Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

被引：32
|
作者：
Tiacci, Enrico [1 ]
De Carolis, Luca [1 ]
Simonetti, Edoardo [1 ]
Merluzzi, Mara [1 ]
Bennati, Antonio [1 ]
Perriello, Vincenzo Maria [1 ]
Pucciarini, Alessandra [1 ]
Santi, Alessia [1 ]
Venanzi, Alessandra [1 ]
Pettirossi, Valentina [1 ]
Schiavoni, Gianluca [1 ]
Tasselli, Luisa [1 ]
Ascani, Stefano [2 ,3 ]
Volpetti, Stefano [4 ]
Falini, Brunangelo [1 ]
机构：
[1] Univ & Hosp Perugia, Hematol, Perugia, Italy
[2] Univ Perugia, Anat Pathol, Perugia, Italy
[3] Hosp Terni, Perugia, Italy
[4] Azienda Sanitaria Univ Integrata, Clin Ematol, Udine, Italy
来源：
LEUKEMIA | 2021年 / 35卷 / 11期
基金：
欧洲研究理事会;
关键词：
MELANOMA; VEMURAFENIB; DIAGNOSIS; THERAPY;
D O I：
10.1038/s41375-021-01210-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3314 / 3318
页数：5
相关论文
共 50 条
  • [31] Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study
    Jones, Jeffrey
    Andritsos, Leslie
    Kreitman, Robert J.
    Ravandi, Farhad
    Schiffer, Charles
    Call, Timothy G.
    Lozanski, Gerard
    Harris, Pamela
    Sexton, Jennifer
    Ruppert, Amy S.
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
  • [32] Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
    Jain, Preetesh
    Ok, Chi Young
    Konoplev, Sergej
    Patel, Keyur P.
    Jorgensen, Jeffrey
    Estrov, Zeev
    Luthra, Raja
    Kantarjian, Hagop
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : E57 - E60
  • [33] A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the FrontLine and Relapsed/Refractory Treatment of Hairy Cell Leukemia
    Hermel, David Jacob
    Ter-Zakarian, Anna
    New, Jacob
    Saven, Alan
    BLOOD, 2023, 142
  • [34] Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
    Witzig, Thomas
    Sokol, Lubomir
    Kim, Won Seog
    Vicente, Fatima de la Cruz
    Garcia-Sancho, Alejandro Martin
    Advani, Ranjana
    Vidal, Jose Maria Roncero
    Navarrete, Raquel de Ona
    Marin-Niebla, Ana
    Izquierdo, Antonia Rodriguez
    Terol, Maria Jose
    Domingo-Domenech, Eva
    Saunders, Andrew
    Bendris, Nawal
    Mackey, Julie
    Leoni, Mollie
    Foss, Francine
    BLOOD ADVANCES, 2024, 8 (17) : 4581 - 4592
  • [35] A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia
    Kadia, Tapan
    Delioukina, Maria L.
    Kantarjian, Hagop M.
    Keating, Michael J.
    Wierda, William G.
    Burger, Jan A.
    Wieland, Scott
    Levitt, Daniel
    BLOOD, 2011, 118 (21) : 1232 - 1233
  • [36] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kevin J. Freise
    Aksana K. Jones
    Doerthe Eckert
    Sven Mensing
    Shekman L. Wong
    Rod A. Humerickhouse
    Walid M. Awni
    Ahmed Hamed Salem
    Clinical Pharmacokinetics, 2017, 56 : 515 - 523
  • [37] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Freise, Kevin J.
    Jones, Aksana K.
    Eckert, Doerthe
    Mensing, Sven
    Wong, Shekman L.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 515 - 523
  • [38] Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
    Baer, Maria R.
    Kogan, Aksinija A.
    Bentzen, Soren M.
    Mi, Tian
    Lapidus, Rena G.
    Duong, Vu H.
    Emadi, Ashkan
    Niyongere, Sandrine
    O'Connell, Casey L.
    Youngblood, Benjamin A.
    Baylin, Stephen B.
    Rassool, Feyruz, V
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1313 - 1322
  • [39] Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma
    Hargrave, Darren R.
    Terashima, Keita
    Hara, Junichi
    Kordes, Uwe R.
    Upadhyaya, Santhosh A.
    Sahm, Felix
    Bouffet, Eric
    Packer, Roger J.
    Witt, Olaf
    Sandalic, Larissa
    Kieloch, Agnieszka
    Russo, Mark
    Cohen, Kenneth J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5174 - +
  • [40] A phase 2 clinical trial of AP23573, an mTOR inhibitor, In patients with relapsed or refractory hematologic malignancies
    Rizzieri, DA
    Feldman, E
    Moore, JO
    Roboz, GJ
    DiPersio, JF
    Gabrail, N
    Stock, W
    Rivera, VM
    Albitar, M
    Bedrosian, CL
    Giles, F
    BLOOD, 2005, 106 (11) : 835A - 836A
12345